Regeneron COVID-19 Antibody Poised To Add Prevention Claim, Sub-Q Formula

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

The company is requesting FDA expand the antibody cocktail to include a COVID prevention claim with a lower 1,200mg dose and a subcutaneously administered formula.

Vector illustration of monoclonal antibody for coronavirus treatment
Regeneron aims to broaden the reach of its COVID-19 antibody • Source: Alamy (srikijt / Alamy Stock Vector/Alamy Stock Vector)

Regeneron Pharmaceuticals, Inc.’s REGEN-COV (casirivimab/imdevimab) could soon be available for a new expanded indication for COVID-19 prevention in certain populations and in a new subcutaneous formulation that could be easier to administer than the existing intravenous formulation. The company said on 12 April it will share Phase III data in the prevention setting with the US Food and Drug Administration and request expansion of the emergency use authorization (EUA) to include a new claim, while the company has already said it will discuss the new formulation and a lower 1,200mg dose with the agency.

Regeneron's REGEN-COV, along with another antibody from Eli Lilly and Company, is already part of the armamentarium used against...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from COVID-19

New COVID-19 Vaccines Shipping Soon, After Rapid Pivot To Address New Strain

 
• By Alaric DeArment

Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.

Pfizer/BioNTech Combo Vaccine Shows Partial Flu Efficacy

 
• By Alaric DeArment

The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.

AstraZeneca Moves To Join Invyvid In COVID-19 Prevention

 
• By Elizabeth Cairns

The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.    

Stock Watch: Thoroughly Moderna Missteps

 
• By Andy Smith

When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains